Genitourinary Cancers | Specialty

FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC

January 9th 2018

The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

January 6th 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the next steps following progression on immunotherapy for patients with bladder cancer.

Dr. McKay Discusses Advances in the Treatment of Metastatic RCC

January 5th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.

Dr. Zhang on the Importance of Adjuvant Clinical Trials in RCC

January 3rd 2018

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the importance of clinical trials in the adjuvant setting of renal cell carcinoma.

Japan Approves Pembrolizumab for Urothelial Carcinoma

January 3rd 2018

The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

January 3rd 2018

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Reflecting Back, Looking Forward in Urology Practice

December 30th 2017

Because of vertical integration, this has allowed us to maintain economic stability in the face of diminishing reimbursement for professional services.

Dr. Agarwal on the CheckMate-214 Trial for Kidney Cancer

December 29th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Dr. McDermott on Immunotherapy as a Standard of Care in RCC

December 28th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Treating Advanced Bladder Cancer in the Future

December 28th 2017

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

December 28th 2017

Immunotherapy in Second-Line Advanced Bladder Cancer

December 28th 2017

Monitoring for Treatment Response in Advanced Bladder Cancer

December 28th 2017

Frontline Immunotherapy in Advanced Bladder Cancer

December 28th 2017

First-Line Chemotherapy in Advanced Bladder Cancer

December 28th 2017

Advanced Bladder Cancer: Predicting Clinical Response

December 28th 2017

Impact of Immunotherapy in Advanced Bladder Cancer

December 28th 2017

Dr. Pal on the Mutational Burden in Bladder Cancer

December 27th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Dr. Voss on the Future of Clinical Trials for Kidney Cancer

December 26th 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Role of PARP Inhibitors Developing in mCRPC

December 26th 2017

Alicia Morgan, MD, discusses the role of PARP inhibitors as a novel treatment strategy for patients with metastatic castration-resistant prostate cancer.